Yonhap Infomax NewsOct 28
Hanmi Pharmaceutical will showcase its blockbuster drugs and innovative pipeline at CPHI Worldwide 2025 in Frankfurt, highlighting its global CDMO capabilities and FDA-approved biologic Rolontis.
#YonhapInfomax #HanmiPharmaceutical #CPHIWorldwide #BlockbusterProducts #Rolontis #CDMOCapabilities #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=87687
Hanmi Pharmaceutical Unveils Blockbuster Products at World's Largest Pharmaceutical Expo

Hanmi Pharmaceutical will showcase its blockbuster drugs and innovative pipeline at CPHI Worldwide 2025 in Frankfurt, highlighting its global CDMO capabilities and FDA-approved biologic Rolontis.

Yonhap Infomax
Yonhap Infomax NewsSep 8, 2025
Hanmi Pharmaceutical has signed a supply agreement with Saudi Arabia's Tabuk Pharmaceuticals to launch its FDA-approved neutropenia biologic 'Rolontis' in the Middle East, marking a major step in the company's global expansion strategy.
#YonhapInfomax #HanmiPharmaceutical #Rolontis #TabukPharmaceuticals #Neutropenia #MiddleEastMarket #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=80643
Hanmi Pharmaceutical Expands Middle East Presence with Neutropenia Drug 'Rolontis'

Hanmi Pharmaceutical has signed a supply agreement with Saudi Arabia's Tabuk Pharmaceuticals to launch its FDA-approved neutropenia biologic 'Rolontis' in the Middle East, marking a major step in the company's global expansion strategy.

Yonhap Infomax